Weekly Digest - March 2025
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - March 2025
19 Mar 2025: AstraZeneca offers early look at Datroway-Tagrisso combo in EGFR lung cancer as phase 3 trial rolls on
- AstraZeneca has released early data from a Phase 2 trial combining Datroway and Tagrisso for EGFR-mutant NSCLC, showing a 36% response rate in patients who progressed on first-line Tagrisso
- The data from the Orchard trial to be presented as part of an abstract for the European Lung Cancer Congress
- Two doses of Datroway were tested, with the 4 mg/kg dose showing a higher 43% response rate compared to the 6 mg/kg dose at 36%
- Investigators recommend the 6 mg/kg dose based on the overall benefit-risk profile, despite the higher response rate at the lower dose
- AstraZeneca’s ongoing Phase 3 Tropion-Lung15 trial is testing Datroway with Tagrisso in post-Tagrisso EGFR-mutant NSCLC, with a primary completion date in June 2026
